These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24157581)

  • 21. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Chihara D; Cheah CY; Westin JR; Fayad LE; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak LW; Wang ML; Romaguera JE
    Br J Haematol; 2016 Jan; 172(1):80-8. PubMed ID: 26648336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
    Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
    Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
    Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
    Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
    Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
    Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
    Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy.
    Brady V; Thosani S; Zhou S; Bassett R; Busaidy NL; Lavis V
    Diabetes Technol Ther; 2014 Dec; 16(12):874-9. PubMed ID: 25321387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive paresthesia and weakness after intrathecal chemotherapy.
    Marshall R; Gupta ND; Palacios E; Neitzschman HR
    J La State Med Soc; 2008; 160(2):92-4. PubMed ID: 18681351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
    Thomas DA; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister FB; Cabanillas FF; Murphy S; Keating MJ; Kantarjian H
    J Clin Oncol; 1999 Aug; 17(8):2461-70. PubMed ID: 10561310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunophenotypic analysis of adult patients with T-cell lymphoblastic lymphoma treated with hyper-CVAD.
    Kato H; Yamamoto K; Kodaira T; Higuchi Y; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Hematology; 2018 Mar; 23(2):83-88. PubMed ID: 28778131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia.
    Kim SY; Park JH; Yoon SY; Cho YH; Lee MH
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):393-398. PubMed ID: 29294168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
    Commander LA; Seif AE; Insogna IG; Rheingold SR
    Br J Haematol; 2010 Aug; 150(3):345-51. PubMed ID: 20528871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
    Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
    Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
    Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
    Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
    Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
    Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
    Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
    J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary T-cell lymphoblastic lymphoma of the cavernous sinus.
    Sadruddin S; Medeiros LJ; DeMonte F
    J Neurosurg Pediatr; 2010 Jan; 5(1):94-7. PubMed ID: 20043743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of modified Hyper-CVAD regimen on non-Hodgkin's lymphoma and safety evaluation].
    Shi W; Shi YK; He XH; Yang JL; Zhang CG; Zhou SY; Dong M; Liu P; Qin Y; Yang S; Gui L; Lv Z
    Ai Zheng; 2009 Oct; 28(10):1083-7. PubMed ID: 19799818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.
    Taylor CW; Dalton WS; Mosley K; Dorr RT; Salmon SE
    Breast Cancer Res Treat; 1997 Jan; 42(1):7-14. PubMed ID: 9116320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
    Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
    Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.